Pulmovant

Pulmovant is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for respiratory infections and chronic lung diseases. Using pulmonary-delivery expertise and proprietary formulation approaches, the company aims to concentrate active agents in the lung to boost local efficacy while minimizing systemic exposure. Pulmovant advances a pipeline of inhaled antibacterial and antiviral candidates through preclinical and clinical development and seeks strategic partnerships to bring new pulmonology medicines to patients.